Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 3
1976 2
1977 1
1978 1
1979 3
1980 2
1983 2
1984 2
1985 1
1988 2
1989 2
1990 1
1991 1
1995 1
1996 1
1997 2
1998 1
1999 2
2000 1
2001 3
2003 1
2004 1
2005 2
2006 3
2007 2
2008 3
2009 2
2010 1
2011 4
2012 3
2013 6
2014 4
2015 4
2016 9
2017 5
2018 5
2019 6
2020 5
2021 7
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "GCGR-related hyperglucagonemia"
Page 1
Pathophysiology of Type 2 Diabetes in Children and Adolescents.
Valaiyapathi B, Gower B, Ashraf AP. Valaiyapathi B, et al. Curr Diabetes Rev. 2020;16(3):220-229. doi: 10.2174/1573399814666180608074510. Curr Diabetes Rev. 2020. PMID: 29879890 Free PMC article.
Besides IR, this is compounded by multiple metabolic defects including beta-cell dysfunction and inadequate insulin secretion, alpha-cell dysfunction, hyperglucagonemia and increased hepatic glucose production, lipotoxicity, inflammation, deficiencies in incretin productio …
Besides IR, this is compounded by multiple metabolic defects including beta-cell dysfunction and inadequate insulin secretion, alpha-cell dy …
Blocking IL-6 signaling improves glucose tolerance via SLC39A5-mediated suppression of glucagon secretion.
Chen W, Cui W, Wu J, Zheng W, Sun X, Zhang J, Shang H, Yuan Y, Li X, Wang J, Hu X, Chen L, Zeng F, Xiao RP, Zhang X. Chen W, et al. Metabolism. 2023 Sep;146:155641. doi: 10.1016/j.metabol.2023.155641. Epub 2023 Jun 26. Metabolism. 2023. PMID: 37380017
BACKGROUND AND AIMS: Hyperinsulinemia, hyperglucagonemia, and low-grade inflammation are frequently presented in obesity and type 2 diabetes (T2D). The pathogenic regulation between hyperinsulinemia/insulin resistance (IR) and low-grade inflammation is well documented in t …
BACKGROUND AND AIMS: Hyperinsulinemia, hyperglucagonemia, and low-grade inflammation are frequently presented in obesity and type 2 d …
Type 2 Diabetes: An Updated Overview.
Ghasemi A, Norouzirad R. Ghasemi A, et al. Crit Rev Oncog. 2019;24(3):213-222. doi: 10.1615/CritRevOncog.2019030976. Crit Rev Oncog. 2019. PMID: 32422019 Review.
Although the pathogenesis of T2D was previously focused on dysfunctions of "ominous triumvirate" (liver, skeletal muscle, and beta-cell), it has been extended to "ominous octet," which includes defects in adipocytes (increased lipolysis), gastrointestinal tract (incretin deficien …
Although the pathogenesis of T2D was previously focused on dysfunctions of "ominous triumvirate" (liver, skeletal muscle, and beta-cell), it …
The Liver-α-Cell Axis and Type 2 Diabetes.
Wewer Albrechtsen NJ, Pedersen J, Galsgaard KD, Winther-Sørensen M, Suppli MP, Janah L, Gromada J, Vilstrup H, Knop FK, Holst JJ. Wewer Albrechtsen NJ, et al. Endocr Rev. 2019 Oct 1;40(5):1353-1366. doi: 10.1210/er.2018-00251. Endocr Rev. 2019. PMID: 30920583 Review.
In patients with T2D, increased secretion of glucagon (hyperglucagonemia) contributes to diabetic hyperglycemia as proven by the significant lowering of fasting plasma glucose levels following glucagon receptor antagonist administration. ...Lipid-induced impairment of hepa …
In patients with T2D, increased secretion of glucagon (hyperglucagonemia) contributes to diabetic hyperglycemia as proven by the sign …
Pathologic pancreatic endocrine cell hyperplasia.
Ouyang D, Dhall D, Yu R. Ouyang D, et al. World J Gastroenterol. 2011 Jan 14;17(2):137-43. doi: 10.3748/wjg.v17.i2.137. World J Gastroenterol. 2011. PMID: 21245985 Free PMC article. Review.
An inactivating mutation of the glucagon receptor causes alpha cell hyperplasia and asymptomatic hyperglucagonemia. Pancreatic polypeptide cell hyperplasia has been described without a clearly-characterized clinical syndrome and hyperplasia of other endocrine cells inside …
An inactivating mutation of the glucagon receptor causes alpha cell hyperplasia and asymptomatic hyperglucagonemia. Pancreatic polype …
Pancreatic α-cell hyperplasia: facts and myths.
Yu R. Yu R. J Clin Endocrinol Metab. 2014 Mar;99(3):748-56. doi: 10.1210/jc.2013-2952. Epub 2013 Nov 27. J Clin Endocrinol Metab. 2014. PMID: 24285676 Review.
CONTEXT: Pancreatic alpha-cell hyperplasia (ACH) was once an esoteric pathological entity, but it has become an important differential diagnosis of hyperglucagonemia after inactivating glucagon receptor (GCGR) genomic mutations were found in patients with ACH. ...The pancr …
CONTEXT: Pancreatic alpha-cell hyperplasia (ACH) was once an esoteric pathological entity, but it has become an important differential diagn …
The biology of glucagon and the consequences of hyperglucagonemia.
Wewer Albrechtsen NJ, Kuhre RE, Pedersen J, Knop FK, Holst JJ. Wewer Albrechtsen NJ, et al. Biomark Med. 2016 Nov;10(11):1141-1151. doi: 10.2217/bmm-2016-0090. Epub 2016 Sep 9. Biomark Med. 2016. PMID: 27611762 Review.
Glucagon increases blood glucose levels through gluconeogenesis and glycogenolysis. Elevated plasma concentrations of glucagon, hyperglucagonemia, may contribute to diabetes. However, hyperglucagonemia is also observed in other clinical conditions than diabetes, inc …
Glucagon increases blood glucose levels through gluconeogenesis and glycogenolysis. Elevated plasma concentrations of glucagon, hypergluc …
Hyperglucagonemia in Pediatric Adiposity Associates With Cardiometabolic Risk Factors but Not Hyperglycemia.
Stinson SE, Jonsson AE, de Retana Alzola IF, Lund MAV, Frithioff-Bøjsøe C, Aas Holm L, Fonvig CE, Pedersen O, Ängquist L, Sørensen TIA, Holst JJ, Christiansen M, Holm JC, Hartmann B, Hansen T. Stinson SE, et al. J Clin Endocrinol Metab. 2022 May 17;107(6):1569-1576. doi: 10.1210/clinem/dgac108. J Clin Endocrinol Metab. 2022. PMID: 35213713 Free PMC article.
CONTEXT: In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. ...CONCLUSION: Compared with normal weight peers, children and adolescents with overweight/obesity had elevated concentrations of fasting glucagon, which corr …
CONTEXT: In adults, hyperglucagonemia is associated with type 2 diabetes, impaired glucose tolerance, and obesity. ...CONCLUSION: Com …
A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues.
Koshy RM, Fernandez CJ, Jacob K. Koshy RM, et al. Curr Drug Saf. 2021;16(2):129-141. doi: 10.2174/1574886315999201105153852. Curr Drug Saf. 2021. PMID: 33153424 Review.
In both T1DM and T2DM, there is accelerated gastric emptying and postprandial hyperglucagonemia. Furthermore, insulin therapy itself is associated with risk of hypoglycemia and weight-gain both of which are barriers to achieving good control. ...
In both T1DM and T2DM, there is accelerated gastric emptying and postprandial hyperglucagonemia. Furthermore, insulin therapy itself …
101 results